578P Increased therapeutic index of muzastotug (ADG126), a masked anti-CTLA-4 antibody, in combination with pembrolizumab (pembro) enables significant clinical benefits and supports further clinical development in patients with metastatic MSS CRC.

Authors :: Li, D.
Kim, S.Y.
Kim, H.K.
Sharma, S.
Shin, S.J.
Lee, J.
Im, S-A.
She, X.K.
Li, Y.
Chung, L.E.C.
Xiao, P.
Liu, G.
Zeng, S.
HuLowe, D.
Chisamore, M.
Luo, P.P.
Zha, J.
Patel, M.R.
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS468-S469. 2p.
Publication Year :: 2024

Full Text Access

Tools